close

Pluristem Therapeutics, Inc., a bio-therapeutics company, engages in the production, research, and development of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the company's proprietary PluriXTM three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The company's principal product in development includes PLX-PAD for people suffering from peripheral artery disease. Its products in development also include PLX-IBD, which targets inflammatory bowel disease; PLX-MS, targeting multiple sclerosis; PLX-BMT that targets the global shortfall of matched tissue for bone marrow transplantation (BMT) by enhancing the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke. The company, formerly known as Pluristem Life Systems, Inc., was founded in 2001 and is based in Haifa, Israel.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	2.19
Volume	52783
Volume Avg	73838
52 Week High	3.66
52 Week Low	1.98
PE	N/A
PE (group average)	57
EPS Year	-0.31
EPS change Q/Q	-36.36%
EPS change Q/Q Yr ago	-46.15%
EPS change Q/Q next Q est	-16.67%
EPS change Y/Y	-27.78%
REV change Q/Q	0%
REV change Q/Q Yr ago	0%
EPS next Q est	-0.06
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%